Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Risk of Zika microcephaly correlates with features of maternal antibodies.

Robbiani DF, Olsen PC, Costa F, Wang Q, Oliveira TY, Nery N Jr, Aromolaran A, do Rosário MS, Sacramento GA, Cruz JS, Khouri R, Wunder EA Jr, Mattos A, de Paula Freitas B, Sarno M, Archanjo G, Daltro D, Carvalho GBS, Pimentel K, de Siqueira IC, de Almeida JRM, Henriques DF, Lima JA, Vasconcelos PFC, Schaefer-Babajew D, Azzopardi SA, Bozzacco L, Gazumyan A, Belfort R Jr, Alcântara AP, Carvalho G, Moreira L, Araujo K, Reis MG, Keesler RI, Coffey LL, Tisoncik-Go J, Gale M Jr, Rajagopal L, Adams Waldorf KM, Dudley DM, Simmons HA, Mejia A, O'Connor DH, Steinbach RJ, Haese N, Smith J, Lewis A, Colgin L, Roberts V, Frias A, Kelleher M, Hirsch A, Streblow DN, Rice CM, MacDonald MR, de Almeida ARP, Van Rompay KKA, Ko AI, Nussenzweig MC.

J Exp Med. 2019 Aug 14. pii: jem.20191061. doi: 10.1084/jem.20191061. [Epub ahead of print]

PMID:
31413072
2.

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Escolano A, Gristick HB, Abernathy ME, Merkenschlager J, Gautam R, Oliveira TY, Pai J, West AP Jr, Barnes CO, Cohen AA, Wang H, Golijanin J, Yost D, Keeffe JR, Wang Z, Zhao P, Yao KH, Bauer J, Nogueira L, Gao H, Voll AV, Montefiori DC, Seaman MS, Gazumyan A, Silva M, McGuire AT, Stamatatos L, Irvine DJ, Wells L, Martin MA, Bjorkman PJ, Nussenzweig MC.

Nature. 2019 Jun;570(7762):468-473. doi: 10.1038/s41586-019-1250-z. Epub 2019 May 29.

PMID:
31142836
3.

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells.

Hartweger H, McGuire AT, Horning M, Taylor JJ, Dosenovic P, Yost D, Gazumyan A, Seaman MS, Stamatatos L, Jankovic M, Nussenzweig MC.

J Exp Med. 2019 Jun 3;216(6):1301-1310. doi: 10.1084/jem.20190287. Epub 2019 Apr 11.

PMID:
30975893
4.

A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Keeffe JR, Van Rompay KKA, Olsen PC, Wang Q, Gazumyan A, Azzopardi SA, Schaefer-Babajew D, Lee YE, Stuart JB, Singapuri A, Watanabe J, Usachenko J, Ardeshir A, Saeed M, Agudelo M, Eisenreich T, Bournazos S, Oliveira TY, Rice CM, Coffey LL, MacDonald MR, Bjorkman PJ, Nussenzweig MC, Robbiani DF.

Cell Rep. 2018 Nov 6;25(6):1385-1394.e7. doi: 10.1016/j.celrep.2018.10.031.

5.

The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination.

Delgado-Benito V, Rosen DB, Wang Q, Gazumyan A, Pai JA, Oliveira TY, Sundaravinayagam D, Zhang W, Andreani M, Keller L, Kieffer-Kwon KR, Pękowska A, Jung S, Driesner M, Subbotin RI, Casellas R, Chait BT, Nussenzweig MC, Di Virgilio M.

Mol Cell. 2018 Nov 15;72(4):636-649.e8. doi: 10.1016/j.molcel.2018.08.042. Epub 2018 Oct 4.

6.

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC, Martin MA.

Nat Med. 2018 May;24(5):610-616. doi: 10.1038/s41591-018-0001-2. Epub 2018 Apr 16.

7.

The microanatomic segregation of selection by apoptosis in the germinal center.

Mayer CT, Gazumyan A, Kara EE, Gitlin AD, Golijanin J, Viant C, Pai J, Oliveira TY, Wang Q, Escolano A, Medina-Ramirez M, Sanders RW, Nussenzweig MC.

Science. 2017 Oct 13;358(6360). pii: eaao2602. doi: 10.1126/science.aao2602. Epub 2017 Sep 21.

8.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Horwitz JA, Bar-On Y, Lu CL, Fera D, Lockhart AAK, Lorenzi JCC, Nogueira L, Golijanin J, Scheid JF, Seaman MS, Gazumyan A, Zolla-Pazner S, Nussenzweig MC.

Cell. 2017 Aug 10;170(4):637-648.e10. doi: 10.1016/j.cell.2017.06.048. Epub 2017 Jul 27.

9.

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R, Azzopardi SA, Uhl LFK, Saeed M, Sevilla-Reyes EE, Agudelo M, Yao KH, Golijanin J, Gristick HB, Lee YE, Hurley A, Caskey M, Pai J, Oliveira T, Wunder EA Jr, Sacramento G, Nery N Jr, Orge C, Costa F, Reis MG, Thomas NM, Eisenreich T, Weinberger DM, de Almeida ARP, West AP Jr, Rice CM, Bjorkman PJ, Reyes-Teran G, Ko AI, MacDonald MR, Nussenzweig MC.

Cell. 2017 May 4;169(4):597-609.e11. doi: 10.1016/j.cell.2017.04.024.

10.

Early antibody therapy can induce long-lasting immunity to SHIV.

Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M, Donau OK, Plishka RJ, Buckler-White A, Seaman MS, Lifson JD, Koup RA, Fauci AS, Nussenzweig MC, Martin MA.

Nature. 2017 Mar 23;543(7646):559-563. doi: 10.1038/nature21435. Epub 2017 Mar 13.

11.

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H, Cesar Lorenzi JC, Halper-Stromberg A, Toth I, Piechocka-Trocha A, Gristick HB, van Gils MJ, Sanders RW, Wang LX, Seaman MS, Burton DR, Gazumyan A, Walker BD, West AP Jr, Bjorkman PJ, Nussenzweig MC.

Sci Transl Med. 2017 Jan 18;9(373). pii: eaal2144. doi: 10.1126/scitranslmed.aal2144.

12.

Sequencing and cloning of antigen-specific antibodies from mouse memory B cells.

von Boehmer L, Liu C, Ackerman S, Gitlin AD, Wang Q, Gazumyan A, Nussenzweig MC.

Nat Protoc. 2016 Oct;11(10):1908-1923. doi: 10.1038/nprot.2016.102. Epub 2016 Sep 15.

PMID:
27658009
13.

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.

Gristick HB, von Boehmer L, West AP Jr, Schamber M, Gazumyan A, Golijanin J, Seaman MS, Fätkenheuer G, Klein F, Nussenzweig MC, Bjorkman PJ.

Nat Struct Mol Biol. 2016 Oct;23(10):906-915. doi: 10.1038/nsmb.3291. Epub 2016 Sep 12.

14.

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, Freund NT, Gitlin AD, Oliveira T, Araki T, Lowe S, Chen ST, Heinemann J, Yao KH, Georgeson E, Saye-Francisco KL, Gazumyan A, Adachi Y, Kubitz M, Burton DR, Schief WR, Nussenzweig MC.

Cell. 2016 Sep 8;166(6):1445-1458.e12. doi: 10.1016/j.cell.2016.07.030.

15.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV.

Cell. 2016 Jun 16;165(7):1609-1620. doi: 10.1016/j.cell.2016.04.050.

16.

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, Horwitz JA, Nogueira L, Golijanin J, Gazumyan A, Ravetch JV, Caskey M, Chakraborty AK, Nussenzweig MC.

Science. 2016 May 20;352(6288):1001-4. doi: 10.1126/science.aaf1279. Epub 2016 May 5.

17.

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.

Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, Golijanin J, Buckler-White A, Sadjadpour R, Wang K, Mankoff Z, Schmidt SD, Lifson JD, Mascola JR, Nussenzweig MC, Martin MA.

Nature. 2016 May 5;533(7601):105-109. doi: 10.1038/nature17677. Epub 2016 Apr 27.

18.

Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory.

Gitlin AD, von Boehmer L, Gazumyan A, Shulman Z, Oliveira TY, Nussenzweig MC.

Immunity. 2016 Apr 19;44(4):769-81. doi: 10.1016/j.immuni.2016.01.011. Epub 2016 Mar 2.

19.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238. eCollection 2015 Oct.

20.

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, McGuire AT, Kulp DW, Oliveira T, Scharf L, Pietzsch J, Gray MD, Cupo A, van Gils MJ, Yao KH, Liu C, Gazumyan A, Seaman MS, Björkman PJ, Sanders RW, Moore JP, Stamatatos L, Schief WR, Nussenzweig MC.

Cell. 2015 Jun 18;161(7):1505-15. doi: 10.1016/j.cell.2015.06.003.

21.

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.

Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR.

J Virol. 2015 Mar;89(5):2659-71. doi: 10.1128/JVI.03136-14. Epub 2014 Dec 17.

22.

Epigenetic targeting of activation-induced cytidine deaminase.

Wang Q, Oliveira T, Jankovic M, Silva IT, Hakim O, Yao K, Gazumyan A, Mayer CT, Pavri R, Casellas R, Nussenzweig MC, Robbiani DF.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18667-72. doi: 10.1073/pnas.1420575111. Epub 2014 Dec 15.

23.

B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.

Qian J, Wang Q, Dose M, Pruett N, Kieffer-Kwon KR, Resch W, Liang G, Tang Z, Mathé E, Benner C, Dubois W, Nelson S, Vian L, Oliveira TY, Jankovic M, Hakim O, Gazumyan A, Pavri R, Awasthi P, Song B, Liu G, Chen L, Zhu S, Feigenbaum L, Staudt L, Murre C, Ruan Y, Robbiani DF, Pan-Hammarström Q, Nussenzweig MC, Casellas R.

Cell. 2014 Dec 18;159(7):1524-37. doi: 10.1016/j.cell.2014.11.013. Epub 2014 Dec 4.

24.

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

Klein F, Nogueira L, Nishimura Y, Phad G, West AP Jr, Halper-Stromberg A, Horwitz JA, Gazumyan A, Liu C, Eisenreich TR, Lehmann C, Fätkenheuer G, Williams C, Shingai M, Martin MA, Bjorkman PJ, Seaman MS, Zolla-Pazner S, Karlsson Hedestam GB, Nussenzweig MC.

J Exp Med. 2014 Nov 17;211(12):2361-72. doi: 10.1084/jem.20141050. Epub 2014 Nov 10.

25.

An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex.

Kracker S, Di Virgilio M, Schwartzentruber J, Cuenin C, Forveille M, Deau MC, McBride KM, Majewski J, Gazumyan A, Seneviratne S, Grimbacher B, Kutukculer N, Herceg Z, Cavazzana M, Jabado N, Nussenzweig MC, Fischer A, Durandy A.

J Allergy Clin Immunol. 2015 Apr;135(4):998-1007.e6. doi: 10.1016/j.jaci.2014.08.030. Epub 2014 Oct 11.

26.

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y.

J Exp Med. 2014 Sep 22;211(10):2061-74. doi: 10.1084/jem.20132494. Epub 2014 Aug 25.

27.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC.

Cell. 2014 Aug 28;158(5):989-999. doi: 10.1016/j.cell.2014.07.043. Epub 2014 Aug 14.

28.

Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection.

Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, Gazumyan A, Darasse-Jèze G, Telerman SB, Breton G, Schreiber HA, Frias-Staheli N, Billerbeck E, Dorner M, Rice CM, Ploss A, Klein F, Swiecki M, Colonna M, Kamphorst AO, Meredith M, Niec R, Takacs C, Mikhail F, Hari A, Bosque D, Eisenreich T, Merad M, Shi Y, Ginhoux F, Rénia L, Urban BC, Nussenzweig MC.

Nat Med. 2013 Jun;19(6):730-8. doi: 10.1038/nm.3197. Epub 2013 May 19.

29.

Mechanism of DNA resection during intrachromosomal recombination and immunoglobulin class switching.

Bothmer A, Rommel PC, Gazumyan A, Polato F, Reczek CR, Muellenbeck MF, Schaetzlein S, Edelmann W, Chen PL, Brosh RM Jr, Casellas R, Ludwig T, Baer R, Nussenzweig A, Nussenzweig MC, Robbiani DF.

J Exp Med. 2013 Jan 14;210(1):115-23. doi: 10.1084/jem.20121975. Epub 2012 Dec 17.

30.

Activation-induced cytidine deaminase in antibody diversification and chromosome translocation.

Gazumyan A, Bothmer A, Klein IA, Nussenzweig MC, McBride KM.

Adv Cancer Res. 2012;113:167-90. doi: 10.1016/B978-0-12-394280-7.00005-1. Review.

31.

Amino-terminal phosphorylation of activation-induced cytidine deaminase suppresses c-myc/IgH translocation.

Gazumyan A, Timachova K, Yuen G, Siden E, Di Virgilio M, Woo EM, Chait BT, Reina San-Martin B, Nussenzweig MC, McBride KM.

Mol Cell Biol. 2011 Feb;31(3):442-9. doi: 10.1128/MCB.00349-10. Epub 2010 Dec 6.

32.

Activation-induced cytidine deaminase targets DNA at sites of RNA polymerase II stalling by interaction with Spt5.

Pavri R, Gazumyan A, Jankovic M, Di Virgilio M, Klein I, Ansarah-Sobrinho C, Resch W, Yamane A, Reina San-Martin B, Barreto V, Nieland TJ, Root DE, Casellas R, Nussenzweig MC.

Cell. 2010 Oct 1;143(1):122-33. doi: 10.1016/j.cell.2010.09.017.

33.

PTIP promotes chromatin changes critical for immunoglobulin class switch recombination.

Daniel JA, Santos MA, Wang Z, Zang C, Schwab KR, Jankovic M, Filsuf D, Chen HT, Gazumyan A, Yamane A, Cho YW, Sun HW, Ge K, Peng W, Nussenzweig MC, Casellas R, Dressler GR, Zhao K, Nussenzweig A.

Science. 2010 Aug 20;329(5994):917-23. doi: 10.1126/science.1187942. Epub 2010 Jul 29.

34.

53BP1 regulates DNA resection and the choice between classical and alternative end joining during class switch recombination.

Bothmer A, Robbiani DF, Feldhahn N, Gazumyan A, Nussenzweig A, Nussenzweig MC.

J Exp Med. 2010 Apr 12;207(4):855-65. doi: 10.1084/jem.20100244. Epub 2010 Apr 5.

35.

Regulation of class switch recombination and somatic mutation by AID phosphorylation.

McBride KM, Gazumyan A, Woo EM, Schwickert TA, Chait BT, Nussenzweig MC.

J Exp Med. 2008 Oct 27;205(11):2585-94. doi: 10.1084/jem.20081319. Epub 2008 Oct 6.

36.

MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation.

Dorsett Y, McBride KM, Jankovic M, Gazumyan A, Thai TH, Robbiani DF, Di Virgilio M, Reina San-Martin B, Heidkamp G, Schwickert TA, Eisenreich T, Rajewsky K, Nussenzweig MC.

Immunity. 2008 May;28(5):630-8. doi: 10.1016/j.immuni.2008.04.002. Epub 2008 May 1.

37.

Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization.

Gazumyan A, Reichlin A, Nussenzweig MC.

J Exp Med. 2006 Jul 10;203(7):1785-94. Epub 2006 Jul 3.

38.

Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation.

McBride KM, Gazumyan A, Woo EM, Barreto VM, Robbiani DF, Chait BT, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8798-803. Epub 2006 May 24.

39.

A B cell receptor with two Igalpha cytoplasmic domains supports development of mature but anergic B cells.

Reichlin A, Gazumyan A, Nagaoka H, Kirsch KH, Kraus M, Rajewsky K, Nussenzweig MC.

J Exp Med. 2004 Mar 15;199(6):855-65.

40.

A cis element in the recombination activating gene locus regulates gene expression by counteracting a distant silencer.

Yannoutsos N, Barreto V, Misulovin Z, Gazumyan A, Yu W, Rajewsky N, Peixoto BR, Eisenreich T, Nussenzweig MC.

Nat Immunol. 2004 Apr;5(4):443-50. Epub 2004 Mar 14.

PMID:
15021880
41.

OcaB is required for normal transcription and V(D)J recombination of a subset of immunoglobulin kappa genes.

Casellas R, Jankovic M, Meyer G, Gazumyan A, Luo Y, Roeder R, Nussenzweig M.

Cell. 2002 Sep 6;110(5):575-85.

42.

RFI-641, a potent respiratory syncytial virus inhibitor.

Huntley CC, Weiss WJ, Gazumyan A, Buklan A, Feld B, Hu W, Jones TR, Murphy T, Nikitenko AA, O'Hara B, Prince G, Quartuccio S, Raifeld YE, Wyde P, O'Connell JF.

Antimicrob Agents Chemother. 2002 Mar;46(3):841-7.

43.

RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein.

Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G.

Chem Biol. 2001 Jul;8(7):645-59.

44.

Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation.

Gazumyan A, Mitsner B, Ellestad GA.

Curr Pharm Des. 2000 Mar;6(5):525-46. Review.

PMID:
10788595
45.

Novel and specific respiratory syncytial virus inhibitors that target virus fusion.

Ding WD, Mitsner B, Krishnamurthy G, Aulabaugh A, Hess CD, Zaccardi J, Cutler M, Feld B, Gazumyan A, Raifeld Y, Nikitenko A, Lang SA, Gluzman Y, O'Hara B, Ellestad GA.

J Med Chem. 1998 Jul 16;41(15):2671-5. No abstract available.

PMID:
9667956
46.

Two geographically distinct isolates of Borrelia burgdorferi from the United States share a common unique ancestor.

Kolbert CP, Podzorski DS, Mathiesen DA, Wortman AT, Gazumyan A, Schwartz I, Persing DH.

Res Microbiol. 1995 Jun;146(5):415-24.

PMID:
8525058
47.
48.

Sequence analysis of the ribosomal RNA operon of the Lyme disease spirochete, Borrelia burgdorferi.

Gazumyan A, Schwartz JJ, Liveris D, Schwartz I.

Gene. 1994 Aug 19;146(1):57-65.

PMID:
7520403
49.

Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions.

Schwartz I, Wormser GP, Schwartz JJ, Cooper D, Weissensee P, Gazumyan A, Zimmermann E, Goldberg NS, Bittker S, Campbell GL, Pavia CS.

J Clin Microbiol. 1992 Dec;30(12):3082-8.

50.

rRNA gene organization in the Lyme disease spirochete, Borrelia burgdorferi.

Schwartz JJ, Gazumyan A, Schwartz I.

J Bacteriol. 1992 Jun;174(11):3757-65.

Supplemental Content

Loading ...
Support Center